{
    "nct_id": "NCT02167256",
    "title": "A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2019-07-25",
    "description_brief": "AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK, namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (A\u00df) peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in preclinical models. This clinical trial will test the potential benefit of AZD0530 for Alzheimer's disease modification.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "AZD0530 100mg/125mg Daily",
                    "description": "AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530."
                },
                {
                    "id": "FG001",
                    "title": "AZD0530 Placebo",
                    "description": "Placebo: 50% of patients will receive placebo treatment for the duration of the study."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "79"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "80"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "58"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "70"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "21"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "10"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "13"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "6"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                }
                            ]
                        },
                        {
                            "type": "non-compliance",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Study partner unable to participate",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "AZD0530 100mg Daily",
                    "description": "Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of \\<100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.\n\nAZD0530 100mg daily: All patients in experimental group (50%) will be started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530."
                },
                {
                    "id": "BG001",
                    "title": "AZD0530 Placebo",
                    "description": "50% of patients will receive placebo treatment for the duration of the study,\n\nPlacebo: 50% of patients will receive placebo treatment for the duration of the study."
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "79"
                        },
                        {
                            "groupId": "BG001",
                            "value": "80"
                        },
                        {
                            "groupId": "BG002",
                            "value": "159"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "40"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "56"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "63"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "119"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "41"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "31"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "72"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "49"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "87"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race/Ethnicity, Customized",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "White (not Hispanic)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "68"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "142"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Black or African American",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Hispanic or Latino",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "American Indian or Alaskan Native",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "More than one race",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Unknown or Not Reported",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Canada",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "76"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "76"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "152"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging",
                    "description": "Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.",
                    "populationDescription": "Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline F18-FDG PET brain scan are included.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "umol/100g/min (change)",
                    "timeFrame": "12 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "AZD0530 100mg/125mg Daily",
                            "description": "AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530."
                        },
                        {
                            "id": "OG001",
                            "title": "AZD0530 Placebo",
                            "description": "Placebo: 50% of patients will receive placebo treatment for the duration of the study."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "72"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.06",
                                            "spread": "0.03"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.05",
                                            "spread": "0.03"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Number of Participants With One or More Serious/Other Adverse Events Subjects With Mild AD as Assessed by Analysis of Adverse Events, Including Symptoms, and Abnormal Findings on Physical and Neurological Examinations, and Standard Labs.",
                    "description": "Assessment of any adverse effects between drug and placebo-treated subjects",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "12 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "AZD0530 100mg/125mg Daily",
                            "description": "AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530."
                        },
                        {
                            "id": "OG001",
                            "title": "AZD0530 Placebo",
                            "description": "Placebo: 50% of patients will receive placebo treatment for the duration of the study."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "79"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "80"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Subjects with one or more adverse events",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "73"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "68"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Subjects with one or more serious adverse events",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "The Effect of Treatment With AZD0530 on Cognitive and Behavioral Function",
                    "description": "The change in cognitive function between baseline and 12 months will be measured by the following tests:\n\n1. Alzheimer Disease Assessment Scale - Cognitive 11 (ADAS-cog11). Measures: Cognitive function Maximum score: 70; Minimum score: 0. Higher score equals worse cognitive function\n2. Mini-Mental State Examination (MMSE) Measures: Cognitive Function Maximum score: 30; Minimum score: 0. Higher score equal better cognitive function\n3. Alzheimer Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Measures: Ability to perform routine daily activities Maximum score: 78; Minimum score: 0. Higher score equals better ability to perform activities of daily living\n4. Clinical Dementia Rating Sum of Boxes (CDR-SO) Measures: Dementia severity Maximum score: 18; Minimum score: 0. Higher score equals more severe dementia.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "12 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "AZD0530 100mg/125mg Daily",
                            "description": "AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530."
                        },
                        {
                            "id": "OG001",
                            "title": "AZD0530 Placebo",
                            "description": "Placebo: 50% of patients will receive placebo treatment for the duration of the study."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "79"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "80"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "ADAS-Cog score",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.26",
                                            "spread": "0.954"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "6.14",
                                            "spread": "0.903"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "MMSE score",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-3.84",
                                            "spread": "0.575"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-3.33",
                                            "spread": "0.543"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "ADCS-ADL",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-9.49",
                                            "spread": "1.263"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-7.64",
                                            "spread": "1.199"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "CDR-SO",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.946",
                                            "spread": "0.292"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.468",
                                            "spread": "0.274"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Percent Change in Brain Volume Before and After Treatment",
                    "description": "Change in volume of pre-defined brain regions between baseline and 12 months of treatment.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "% change in volume",
                    "timeFrame": "12 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "AZD0530 100mg/125mg Daily",
                            "description": "AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530."
                        },
                        {
                            "id": "OG001",
                            "title": "AZD0530 Placebo",
                            "description": "Placebo: 50% of patients will receive placebo treatment for the duration of the study."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "57"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Entorhinal volume change",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-2.3939",
                                            "spread": "1.8138"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-3.1002",
                                            "spread": "1.7446"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Whole brain volume change",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.5993",
                                            "spread": "1.0569"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.7077",
                                            "spread": "1.0922"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Hippocampus volume change",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.8931",
                                            "spread": "1.8089"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.542",
                                            "spread": "1.9893"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cerebrospinal Fluid Levels of Total Tau, Phospho-tau (p-Tau), and Amyloid-beta 1-42 (Abeta 1-42)",
                    "description": "Measure concentration of Tau and Amyloid-beta 1-42 biomarkers in the cerebrospinal fluid between baseline and 12 months of treatment",
                    "populationDescription": "Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline cerebrospinal fluid analysis were included.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "pg/ml",
                    "timeFrame": "12 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "AZD0530 100mg/125mg Daily",
                            "description": "AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530."
                        },
                        {
                            "id": "OG001",
                            "title": "AZD0530 Placebo",
                            "description": "Placebo: 50% of patients will receive placebo treatment for the duration of the study."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "17"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "17"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "CSF Total tau",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "91.7448",
                                            "spread": "212.7244"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.2091",
                                            "spread": "131.2533"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "CSF p-Tau",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.5837",
                                            "spread": "17.7504"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.9986",
                                            "spread": "13.7311"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "CSF Abeta 1-42",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.3383",
                                            "spread": "47.3549"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.3758",
                                            "spread": "43.3233"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging",
                    "description": "The results from the primary outcome with brain FDG-PET imaging was analyzed by ApoE genotype. Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.",
                    "populationDescription": "Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline F18-FDG PET brain scan are included.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "umol/100g/min (change)",
                    "timeFrame": "12 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "AZD0530 100mg/125mg Daily",
                            "description": "AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530."
                        },
                        {
                            "id": "OG001",
                            "title": "AZD0530 Placebo",
                            "description": "Placebo: 50% of patients will receive placebo treatment for the duration of the study."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "72"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "APOE4 carrier FDG-PET measure from baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "37"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "47"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.06",
                                            "spread": "0.03"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.05",
                                            "spread": "0.03"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "APOE4 non-carrier FDG-PET measure from baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "22"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "25"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.06",
                                            "spread": "0.03"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.05",
                                            "spread": "0.03"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "Adverse events data were collected over a period of 1 year (study duration)",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "AZD0530 100mg/125mg Daily",
                    "description": "AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily\n\nAZD0530 125mg daily: Patients with plasma drug level \\<100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.",
                    "deathsNumAffected": 1,
                    "deathsNumAtRisk": 79,
                    "seriousNumAffected": 12,
                    "seriousNumAtRisk": 79,
                    "otherNumAffected": 73,
                    "otherNumAtRisk": 79
                },
                {
                    "id": "EG001",
                    "title": "AZD0530 Placebo",
                    "description": "Placebo: 50% of patients will receive placebo treatment for the duration of the study.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 80,
                    "seriousNumAffected": 7,
                    "seriousNumAtRisk": 80,
                    "otherNumAffected": 65,
                    "otherNumAtRisk": 80
                }
            ],
            "seriousEvents": [
                {
                    "term": "Infections and infestations",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Cardiac disorders",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Injury, poisoning and procedural complications",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Psychiatric disorders",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Blood and lymphatic system disorders",
                    "organSystem": "Blood and lymphatic system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Nervous system disorders",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Reproductive system and breast disorders",
                    "organSystem": "Reproductive system and breast disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Gastrointestinal disorders",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Musculoskeletal and connective tissue disorders",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 80
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Gastrointestinal disorders",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 38,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 23,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Psychiatric disorders",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 27,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 17,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Skin and subcutaneous tissue disorders",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 18,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 10,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Metabolism and nutrition disorders",
                    "organSystem": "Metabolism and nutrition disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 11,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Investigations",
                    "organSystem": "Investigations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 24,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 17,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "General disorders and administration site conditions",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 15,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 9,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Respiratory, thoracic and mediastinal disorders",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 13,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 7,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Infections and infestations",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 28,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 24,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Renal and urinary disorders",
                    "organSystem": "Renal and urinary disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Eye disorders",
                    "organSystem": "Eye disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Nervous system disorders",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 18,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 16,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Blood and lymphatic system disorders",
                    "organSystem": "Blood and lymphatic system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Ear and labyrinth disorders",
                    "organSystem": "Ear and labyrinth disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Reproductive system and breast disorders",
                    "organSystem": "Reproductive system and breast disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Immune system disorders",
                    "organSystem": "Immune system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Endocrine disorders",
                    "organSystem": "Endocrine disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Cardiac disorders",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 6,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Vascular disorders",
                    "organSystem": "Vascular disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 6,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 8,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Injury, poisoning and procedural complications",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 13,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 22,
                            "numAtRisk": 80
                        }
                    ]
                },
                {
                    "term": "Musculoskeletal and connective tissue disorders",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 14,
                            "numAtRisk": 79
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 24,
                            "numAtRisk": 80
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Stephen Strittmatter",
                "organization": "Yale University",
                "email": "stephen.strittmatter@yale.edu",
                "phone": "2037854878"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "AZD0530 (saracatinib)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The description states AZD0530 is an inhibitor of Src/Abl family kinases and that a specific Src family kinase (Fyn) is implicated in amyloid-\u03b2\u2013mediated synaptotoxicity; the trial tests AZD0530 for Alzheimer\u2019s disease modification, i.e., targeting AD pathology rather than only symptomatic cognitive enhancement. \ue200cite\ue202turn0search6\ue202turn0search1\ue201.",
        "Act: AZD0530 is the small-molecule Src-family kinase inhibitor saracatinib (oral drug repurposed from oncology) and was evaluated in Phase Ib and Phase IIa AD trials including an 18F\u2011FDG PET, safety, and tolerability study \u2014 the trial title matches NCT02167256 / published reports. This identifies it as a disease\u2011targeted small molecule (not a biologic). \ue200cite\ue202turn0search5\ue202turn0search0\ue201.",
        "Reflect: Classification confirmed \u2014 AZD0530/saracatinib is a small\u2011molecule kinase inhibitor intended to modulate an AD\u2011relevant pathological pathway (Fyn downstream of A\u03b2), so it fits the 'disease\u2011targeted small molecule' category rather than biologic, symptomatic cognitive enhancer only, or neuropsychiatric treatment. Key supporting sources: Phase Ib CNS availability report and Phase IIa randomized trial report / trial registry. \ue200cite\ue202turn0search1\ue202turn0search0\ue202turn0search5\ue201."
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: AZD0530 (saracatinib) is an oral small\u2011molecule inhibitor of Src family tyrosine kinases (including Fyn), and Fyn mediates amyloid\u2011\u03b2 oligomer\u2013triggered postsynaptic signaling that causes synaptic dysfunction and loss \u2014 the mechanism is aimed at preventing synaptotoxicity and preserving synaptic function rather than directly removing amyloid plaques. \ue200cite\ue202turn0search6\ue202turn2search7\ue201",
        "Act: Extracted details from the trial description \u2014 the investigational drug is AZD0530 (saracatinib), a disease\u2011targeted small molecule Src/Fyn kinase inhibitor; the Phase IIa study (NCT02167256) evaluated 18F\u2011FDG PET, safety and tolerability in mild AD patients, matching the provided trial title and registry entry. Based on the drug\u2019s mechanism (modulation of Fyn\u2011dependent synaptic signaling), the most specific CADRO match is M) Synaptic Plasticity/Neuroprotection. \ue200cite\ue202turn0search3\ue202turn1search3\ue201",
        "Reflect: Confirming the classification \u2014 although the Fyn pathway is activated downstream of amyloid\u2011\u03b2, AZD0530 does not directly target amyloid\u2011beta itself (CADRO A), nor is it a biologic or a general multi\u2011target neuropsychiatric/symptomatic agent; its therapeutic intent is to protect synapses and modulate synaptic signaling implicated in AD pathogenesis, fitting CADRO M. Supporting preclinical and early clinical rationale and summaries are documented in the literature and trial registry. \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "Web search results (key sources used):",
        "- AZD0530 / saracatinib mechanism (Src family / Fyn inhibitor). \ue200cite\ue202turn0search6\ue201",
        "- ALZFORUM summary of saracatinib (preclinical effects on synapses, Fyn link). \ue200cite\ue202turn0search1\ue201",
        "- Phase Ib study reporting CNS availability, safety and rationale for Phase IIa in AD. \ue200cite\ue202turn0search3\ue201",
        "- Clinical trial registry entry for the Phase IIa 18F\u2011FDG PET, safety and tolerability study (NCT02167256). \ue200cite\ue202turn1search3\ue201",
        "- Primary literature showing amyloid\u2011\u03b2 oligomers activate Fyn via PrP(C) leading to synaptic impairment. \ue200cite\ue202turn2search7\ue201"
    ]
}